Tenaya Therapeutics, Inc., a biotechnology company based in San Francisco, United States, recently disclosed its financial results and key program updates for the fourth quarter and full year of 2025. The company, which is listed on the Nasdaq, focuses on discovering, developing, and delivering curative therapies targeting the underlying factors of heart disease. Their mission is to improve patient outcomes and overall health in the United States.
In a March 11, 2026, filing, Tenaya highlighted encouraging data from its two lead gene-therapy programs: TN-201 for hypertrophic cardiomyopathy and TN-401 for arrhythmogenic right-ventricular cardiomyopathy. These updates were presented at the American Heart Association’s scientific sessions and published in a peer-reviewed journal. Additionally, the company announced new preclinical evidence supporting its small-molecule candidate TN-301 in Duchenne muscular dystrophy models. Plans are underway to advance TN-301 toward clinical testing for heart-failure and muscular disease indications.
Financially, Tenaya disclosed a successful public offering in December 2025, which raised approximately $55 million. The company also announced an ongoing research collaboration with Alnylam Pharmaceuticals, which includes an upfront payment and future milestone opportunities. As of year-end, Tenaya’s cash position is projected to support operations through the second half of 2027. The company reported a decline in research and development expenses compared to the prior year and a net loss for 2025 that was less than the previous year’s loss.
Regulatory designations for Tenaya’s gene-therapy programs include fast-track and orphan status. The company outlined upcoming data releases and regulatory alignment activities planned for 2026. With a market capitalization of approximately $193.3 million and a close price of $0.8524 on March 12, 2026, Tenaya Therapeutics continues to focus on advancing its innovative therapies to address critical unmet medical needs in cardiovascular and muscular diseases.
